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Isoprenoid Biosynthesis Inhibition Disrupts Rab5 Localization and
Food Vacuolar Integrity in Plasmodium falciparum
Ruth Howe,a Megan Kelly,a John Jimah,b Dana Hodge,a Audrey R. Odoma,b

The antimalarial agent fosmidomycin is a validated inhibitor of the nonmevalonate isoprenoid biosynthesis (methylerythritol
4-phosphate [MEP]) pathway in the malaria parasite, Plasmodium falciparum. Since multiple classes of prenyltransferase inhibitors kill P. falciparum, we hypothesized that protein prenylation was one of the essential functions of this pathway. We found
that MEP pathway inhibition with fosmidomycin reduces protein prenylation, confirming that de novo isoprenoid biosynthesis
produces the isoprenyl substrates for protein prenylation. One important group of prenylated proteins is small GTPases, such as
Rab family members, which mediate cellular vesicular trafficking. We have found that Rab5 proteins dramatically mislocalize
upon fosmidomycin treatment, consistent with a loss of protein prenylation. Fosmidomycin treatment caused marked defects in
food vacuolar morphology and integrity, consistent with a defect in Rab-mediated vesicular trafficking. These results provide
insights to the biological functions of isoprenoids in malaria parasites and may assist the rational selection of secondary agents
that will be useful in combination therapy with new isoprenoid biosynthesis inhibitors.

S

evere malaria due to infection with the protozoan parasite
Plasmodium falciparum has a significant impact on global
health (1). Infections with P. falciparum contribute nearly 1 million deaths per year (2). Malaria control efforts are hampered by
resistance to existing antimalarial agents, particularly chloroquine
(3, 4). Clinical resistance to the more recently introduced artemisinin-based therapies has already been reported, highlighting the
ongoing need to identify and exploit new targets for antimalarial
drug development (5, 6).
Isoprenoid biosynthesis is a promising antimalarial drug target. Unlike mammalian cells, plasmodia do not use the classically
described metabolic route via mevalonate. Instead, the malaria
parasite produces isoprenoids through a mevalonate-independent pathway, which proceeds through a different key metabolite,
methylerythritol 4-phosphate (MEP) (7, 8). P. falciparum requires
isoprenoid biosynthesis through the MEP pathway during intraerythrocytic development, the stage of parasite growth responsible for the clinical symptoms of malaria. The genetic locus for the
first dedicated enzyme of this pathway (deoxyxylulose-5-phosphate reductoisomerase [DXR]) is resistant to genetic disruption
in P. falciparum and the related apicomplexan Toxoplasma gondii,
and chemical inhibition of the MEP pathway by the small molecule fosmidomycin is lethal to malaria parasites (8–10). Fosmidomycin treatment of cells inhibits two enzymes of the MEP pathway
(DXR and methylerythritol phosphate cytidyltransferase [IspD]),
and growth inhibition by fosmidomycin is rescued by supplementation with downstream isoprenoids, such as isopentenyl pyrophosphate and geranylgeraniol (11, 12). Altogether, these studies
validate the MEP pathway as an antimalarial drug target and establish the specificity of fosmidomycin as a chemical probe to
address isoprenoid biology in P. falciparum.
Isoprenoids comprise a diverse class of cellular molecules, with
over 20,000 natural isoprenoids described (13). The pathogenic
stage of P. falciparum occupies a highly unusual ecological niche
within human red blood cells and has several peculiar metabolic
features that make it unclear which isoprenoids are essential in P.
falciparum. For example, although isoprenoids contribute to
membrane stability (as cholesterol), the malaria parasite acquires
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cholesterol from host cells and does not synthesize sterols de novo
(14). In contrast, both ubiquinone biosynthesis and protein prenylation appear to be required for P. falciparum development.
Ubiquinone, derived from isoprenoids, is an electron carrier and a
necessary cofactor for the P. falciparum pyrimidine biosynthesis
enzyme dihydroorotate dehydrogenase (DHODH), which is vital
for malaria parasite growth (15). Protein prenylation is the posttranslational modification of proteins, such as small GTPases,
with either farnesyl (15-carbon) or geranylgeranyl (20-carbon)
isoprenyl groups. Isoprenyl moieties are covalently attached to
C-terminal cysteines by one of three well-characterized prenyltransferases, which are expressed during the intraerythrocytic cycle (16, 17). Multiple classes of prenyltransferase inhibitors kill the
malaria parasite, strongly suggesting that protein prenylation is an
essential function of isoprenoid biosynthesis in malaria (18–21).
In our approach, we used the isoprenoid biosynthesis inhibitor
fosmidomycin to address the role of protein prenylation as an
essential function of isoprenoids in P. falciparum. In these studies,
we confirm that ubiquinone is not the sole required isoprenoid in
malaria parasites. We demonstrate that de novo isoprenoid biosynthesis via the MEP pathway generates the isoprenyl precursors
for protein prenylation and that nonprenylated proteins are mislocalized upon fosmidomycin treatment. Finally, we demonstrate
that inhibition of isoprenoid biosynthesis causes a late developmental arrest and vesicular trafficking defect in malaria parasites,
consistent with a loss of protein prenylation.
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falciparum Rab5a (Pf-Rab5a) and Pf-Rab5c were kindly provided by Gordon Langsley (Institut Cochin, France) (30) and were used at 1:500 and
1:1,000 dilutions, respectively. The secondary antibody used was Alexa
Fluor 488 goat anti-rabbit IgG(H⫹L) (catalog number A11008; Invitrogen) at a 1:500 dilution, and Hoechst 33258 was used as a nuclear counterstain. Images were obtained with an Olympus Fluoview FV1000 confocal microscope. All images were analyzed by using ImageJ software (31).
Minimal adjustments in brightness and contrast were employed and were
applied equally to all samples.
For ultrastructural analysis, Plasmodium-infected red blood cells were
fixed in 1% glutaraldehyde (Polysciences Inc., Warrington, PA)–1% osmium tetroxide (Polysciences Inc.) in 50 mM phosphate buffer (pH 7.2)
for 1 h at 4°C. This low-osmolarity fixation was used to remove dense,
soluble cytoplasmic components, allowing unobscured membrane analysis. Cells were washed in phosphate buffer and rinsed extensively in distilled water (dH2O) prior to en bloc staining with 1% aqueous uranyl
acetate (Ted Pella Inc., Redding, CA) for 1 h. Following several rinses in
dH2O, samples were dehydrated in a graded series of ethanol and embedded in Eponate 12 resin (Ted Pella Inc.). Sections of 90 nm were cut,
stained with uranyl acetate and lead citrate, and viewed on a Jeol 1200 EX
transmission electron microscope (Jeol USA, Peabody, MA) at an accelerating voltage of 80 kV.

RESULTS

Electron transport bypass does not confer resistance to inhibition of isoprenoid biosynthesis. De novo isoprenoid biosynthesis
through the MEP pathway is an essential metabolic pathway in
malaria parasites. Because this pathway produces a large number
of compounds, we are interested in which of these is required for
development of the malaria parasite, P. falciparum. The isoprenoid ubiquinone is an electron acceptor for mitochondrial
electron transport and is a necessary cofactor for the essential
pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase
(DHODH). The cytochrome bc1 complex of the electron transport chain is the target of the antimalarial agent atovaquone (32).
Malaria parasites engineered to heterologously express a yeast dihydroorotate dehydrogenase (yDHODH) homolog, which does
not require a ubiquinone cofactor, can survive without mitochondrial respiration and are resistant to atovaquone (23). Ubiquinone
biosynthesis is therefore expected to be one of the essential functions of isoprenoids in malaria parasites.
In order to determine whether there are other essential functions of isoprenoids, we evaluated whether yDHODH expression
also conferred resistance to inhibition of isoprenoid biosynthesis,
using the validated MEP pathway inhibitor fosmidomycin. We
obtained a strain of P. falciparum that heterologously expresses
yDHODH. We independently confirmed that this strain is resistant to atovaquone, as was previously shown (data not shown)
(23). We compared the fosmidomycin concentration that inhibited 50% of growth (IC50) at 3 days between the yDHODH-expressing strain and its parental control line. The yDHODH-expressing strain was as sensitive to fosmidomycin as the control
parasite line (mean IC50 of 1.2 M [95% confidence interval {CI},
0.66 to 2.3], compared to the mean IC50 of the wild-type strain,
0.88 M [95% CI, 0.67 to 1.14]) (Fig. 1). Since expression of
yDHODH does not confer fosmidomycin resistance, ubiquinone
production is not likely to be the only essential function of isoprenoid biosynthesis in malaria parasites.
Inhibition of isoprenoid biosynthesis reduces protein prenylation. We evaluated whether inhibition of de novo isoprenoid
biosynthesis by fosmidomycin, which should reduce the concentration of isoprenyl precursors, would reduce protein prenylation.
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Materials. All buffer components, salts, and enzyme substrates were purchased from Sigma, unless otherwise indicated.
Plasmodium falciparum culture and strains. P. falciparum strains
were cultured in vitro in human erythrocytes, as described previously (12),
with the following modifications: a 5% O2–5% CO2–90% N2 atmosphere
in RPMI 1640 medium supplemented with 27 mM sodium bicarbonate,
11 mM glucose, 5 mM HEPES, 1 mM sodium pyruvate, 0.37 mM hypoxanthine, 0.01 mM thymidine, 0.25 mg/ml gentamicin (Goldbio), and
0.5% Albumax (Invitrogen). The following strains were obtained from the
Malaria Research and Reference Reagent Resource Center (MR4): wildtype strain 3D7 (MRA-102), D10 ACP-(leader)-GFP (MRA-568 [22]),
and D10 ACP-(signal)-GFP (MRA-570 [22]). The following strains were
kindly provided by Akhil Vaidya (Drexel University, Philadelphia, PA)
(23): parental clone D10 and transgenic D10⫹pHHyDHOD-GFP (which
heterologously expresses yeast DHODH [yDHODH]). The following
strain was kindly provided by Daniel Goldberg (Washington University,
St. Louis, MO): 3D7⫹pPlasmepsin-II-GFP (24).
Flow cytometric analysis. Cultures were treated twice with a 5% (wt/
vol) D-sorbitol solution during ring-stage growth to produce a ⬎90%
synchronized culture. Each culture was resynchronized 24 h later by magnetic separation (MS) with MS columns and a MiniMACS separator
(Miltenyi Biotech) to remove early-stage parasites, as previously described (25, 26). Giemsa-stained smears were used to monitor growth.
Cell cycle analysis was performed using ⬎95% synchronized Plasmodium
falciparum 3D7 cultures. Four independent strains were split to 1% parasitemia (percentage of infected erythrocytes), and each was divided into
four separate treatment groups (no drug, 5 M fosmidomycin [Invitrogen], 5 M fosmidomycin plus 5 M geranylgeraniol, or 5 M geranylgeraniol). At each time point, 100 l of each culture was fixed with an
equivalent volume of fixative solution (8% paraformaldehyde– 0.015%
glutaraldehyde in phosphate-buffered saline [PBS]). DNA content was
determined by staining with the fluorophore acridine orange (1.5 g/ml;
Invitrogen), followed by resolution on a BD-FACS flow cytometer, as
previously described (27). Data analysis was performed by using FlowJo
(TreeStar Inc., Ashland, OR) and Prism 5 (GraphPad Software, La Jolla,
CA) software.
Immunoblot analysis. P. falciparum 3D7 parasites were grown to approximately 10% parasitemia, synchronized by treatment with sorbitol as
described above. Newly invaded ring-stage parasites were treated with or
without 5 M fosmidomycin for 24 h. Host erythrocytes were lysed with
0.1% saponin, and parasites were harvested by centrifugation, washed
with PBS, and then stored at ⫺80°C until use. Parasite pellets were lysed
by sonication in lysis buffer (10% glycerol, 0.1% Triton X-100, 20 mM
HEPES [pH 7.5], 150 mM sodium chloride, and protease inhibitors
[Complete EDTA-free tablets; Roche]). Immunoblotting was performed
as previously described, using rabbit antifarnesyl polyclonal antibody at a
1:500 dilution (Abcam, Cambridge, MA), rabbit anti-Plasmodium falciparum EIF1␣ antibody (kindly provided by Daniel Goldberg, Washington
University [28]) at a 1:3,000 dilution, and horseradish peroxidase (HRP)conjugated goat anti-rabbit immunoglobulin polyclonal antibody at a
1:10,000 dilution (Invitrogen).
Microscopic analysis. P. falciparum parasites were synchronized by
treatment with sorbitol as described above. Newly invaded ring-stage parasites were treated with or without 5 M fosmidomycin, 5 M fosmidomycin plus 5 M geranylgeraniol, or 5 M wortmannin. Live cells were
visualized as previously described (24), and images of live cells and Giemsa-stained slides were obtained with an Olympus BH8 microscope.
Live cells were stained with Lysotracker Red DND-99 (LR) (Molecular
Probes) at 75 nM for 15 min, washed in an equal volume of fresh culture
medium, and visualized immediately for no longer than 15 min. For immunofluorescence microscopy, cells were fixed in 4% paraformaldehyde
with or without 0.0075% glutaraldehyde and stored at 4°C. Fixed parasites
were permeabilized, blocked, and incubated with antibodies, as previously described (29). Rabbit polyclonal antibodies against recombinant P.
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FIG 1 Bypass of electron transport does not confer fosmidomycin resistance.

We analyzed whole protein lysates from parasites grown with and
without fosmidomycin (5 M, approximately five times the IC50)
by immunoblotting with a rabbit polyclonal antifarnesyl antibody
that recognizes both farnesyl and geranylgeranyl groups. Previous
experiments in which P. falciparum was metabolically labeled with
[3H]farnesol demonstrated a characteristic protein banding pattern of two dominant prenylated bands, one at 45 kDa and the
other at 20 to 25 kDa (16, 33). We found that immunoblotting of
parasite lysates with antifarnesyl antibody recapitulated this banding pattern, consistent with the identification of these bands as
prenylated proteins (Fig. 2). We used a densitometric evaluation
of band intensities to compare prenylation with and without fosmidomycin treatment. The intensity of antifarnesyl staining of the
⬃25-kDa lower band was reduced by 97% following fosmidomycin treatment (normalized to the density of control Pf-EF1␣ immunoblotting of the same blot). The intensity of the upper 45-kDa
band, the identity of which is unknown, was reduced by 30%
following fosmidomycin treatment. These results indicate that the
isoprenyl moieties used for protein prenylation are derived from
de novo isoprenoid biosynthesis in P. falciparum and that inhibition of isoprenoid biosynthesis reduces protein prenylation.
Rab GTPases are mislocalized when isoprenoid biosynthesis
is inhibited. Fosmidomycin inhibited protein prenylation and
particularly reduced prenylation of proteins of around 25 kDa.
The malaria parasite expresses at least 11 small GTPases with predicted molecular masses of between 23 and 27 kDa, each of which
is predicted to be geranylgeranylated (34, 35). These proteins
likely comprise the dominant band that labels with [3H]farnesol
and are recognized by antifarnesyl antibodies at 25 kDa (16). Since
protein prenylation is typically required for the localization and
function of small GTPases, such as Rab5 family members, we examined the localization of two candidate geranylgeranyltransferase substrates, Pf-Rab5a and Pf-Rab5c. Rab5 proteins are prototypical markers of early endosomal vesicles in most eukaryotic
cells, and Pf-Rab5a was previously localized by immunoelectron
microscopy to small hemoglobin-containing vesicles in P. falciparum (36). Pf-Rab5a and Pf-Rab5c were dispersed in punctae
throughout malaria parasite cells (Fig. 3). Upon fosmidomycin
treatment, a dramatic mislocalization of Rab5a occurred in the
majority of treated cells, such that Rab5a was no longer present
within the parasite cell but instead was found at the membrane of
the host erythrocyte. Similarly, fosmidomycin treatment mislocalized Rab5c, which became diffusely localized throughout both
the parasite cell and the host erythrocyte cytoplasm. Previous
studies demonstrated that the antimalarial effects of fosmidomycin are rescued by medium supplementation with the downstream
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FIG 2 Fosmidomycin treatment inhibits protein prenylation. (A) Antifarnesyl
immunoblot of extracts with or without treatment with 5 M fosmidomycin
(FSM) for 24 h. (B) Blot from panel A reprobed with antibodies to Pf-EIF1␣ to
indicate equivalent protein loading. Results are representative of at least three
independent biological replicates.

isoprenol geranylgeraniol, which we confirmed (see Fig. S1 in the
supplemental material) (11, 12). Localizations of both Rab5a and
Rab5c were restored by medium supplementation with geranylgeraniol, demonstrating that this effect of fosmidomycin was
also due to inhibition of isoprenoid biosynthesis. To quantify
these observations, a series of independent representative images
(⬎50 cells under each condition) were scored on a scale of 1 to 3
(where 1 represents a typical intracellular localization and 3 represents primarily erythrocyte membrane staining) by a trained
observer who was blinded to the treatment conditions (Fig. 3C).
The cellular distributions of Pf-Rab5a and Pf-Rab5c were significantly altered upon fosmidomycin treatment (P ⬍ 0.001 for each
[t test]).
Inhibition of isoprenoid biosynthesis causes developmental
arrest during schizogony. Our data indicate that the MEP pathway generates the isoprenyl groups for protein prenylation in P.
falciparum and that candidate prenylated proteins are mislocalized upon fosmidomycin treatment. We next evaluated the biological effects of isoprenoid depletion on P. falciparum to assess
whether the phenotype of fosmidomycin-treated parasites was
consistent with a loss of prenylated protein function. We examined gross effects on parasite development using Giemsa staining
and light microscopy of parasites with or without fosmidomycin
treatment. Within the erythrocyte host cell, untreated P. falciparum parasites mature from newly invaded parasites with a typical
ring morphology into multinucleated schizonts. This is followed
by egress as merozoites and reinvasion, in a cycle that typically
takes approximately 48 h. We found that fosmidomycin-treated
parasites have normal gross development over the first 24 h but
arrest in the first cell cycle as schizonts, after the onset of nuclear
division but prior to segmentation of daughter merozoites (Fig.
4). To quantify the stage of this arrest, we generated highly synchronized parasite cultures and monitored DNA content
throughout the development of each culture using acridine orange staining and flow cytometry. At the initial time point (time
zero), each culture was highly enriched for ring-stage parasites
(⬎95% of total cells), which had not yet begun DNA replication
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Shown are data for growth inhibition by the isoprenoid biosynthesis inhibitor
fosmidomycin (FSM) in P. falciparum parasites (control) compared to parasites that heterologously express yeast dihydroorotate dehydrogenase, which
does not require ubiquinone (control ⫹ yDHODH). Results are the means
and standard deviations from three independent biological replicates.

Howe et al.

antibody in untreated parasites (control) compared to fosmidomycin-treated (⫹FSM) and fosmidomycin- and geranylgeraniol-treated (⫹FSM ⫹GG-ol)
parasites. FITC, fluorescein isothiocyanate. (C) Blinded scoring of ⬎50 cells under each condition for severity of mislocalization of Rab5 (1, typical cellular
punctae within parasite; 2, partial mislocalization to erythrocyte or erythrocyte membrane; 3, severe mislocalization to erythrocyte or erythrocyte membrane).
ⴱ, P ⬍ 0.001 compared to untreated conditions.

(pre-S phase). Control and geranylgeraniol-treated parasites
completed multiple rounds of DNA replication and produced
daughter parasites (returning to pre-S phase). In contrast, the majority (⬎80%) of fosmidomycin-treated parasites entered S phase
but failed to develop further (Fig. 5). These effects of fosmidomycin were reversed by medium supplemented with a downstream
isoprenol, geranylgeraniol (Fig. 5), confirming that they are specific to isoprenoid blockade. Fosmidomycin-treated parasites arrest with an average DNA content of approximately 9.1 ⫾ 1.0 n
(where n refers to the haploid DNA content of ring-stage parasites), compared to control parasites, which contain an average
maximum DNA content of 15.6 ⫾ 1.3 n (see Fig. S2 in the supplemental material).
Inhibition of isoprenoid biosynthesis disrupts food vacuolar
morphology. Because Rab GTPases are required for vesicular trafficking in most eukaryotic cells, we further examined the ultrastructural effects of isoprenoid biosynthesis inhibition on P. falciparum parasites. Highly synchronized cultures (enriched for
ring-stage parasites) were cultured with or without fosmidomycin
and then fixed at the indicated time points. Typical cellular features of P. falciparum include nuclei, mitochondria, apicoplast

FIG 4 Fosmidomycin treatment causes growth arrest of malaria parasites
during schizogony. Shown are Giemsa-stained light micrographs of synchronized ring-stage parasites at the indicated time points of culture for comparison of untreated parasites (A) to those treated with 5 M fosmidomycin (B) or
5 M fosmidomycin plus 5 M the downstream isoprenol geranylgeraniol
(C). Images of representative cells are indicative of results from at least five
independent biological replicates.

218

ec.asm.org

organelles, as well as the food vacuole (FV), where hemoglobin
digestion occurs. We found that fosmidomycin-treated parasites
were ultrastructurally indistinguishable from control parasites at
early stages of development through early trophozoite stages
(through 16 h of drug treatment [data not shown]), including
normal formation and development of the digestive FV. By 24 h of
treatment, however, fosmidomycin-treated parasites began to
demonstrate morphological abnormalities of the FV (Fig. 6). A
typical malarial FV contains a single focus of hemozoin pigment
crystals (the final product of heme detoxification from hemoglobin digestion) within a distinct food vacuolar membrane. In contrast, fosmidomycin-treated parasites demonstrated a variety of
abnormal FV morphologies. In less severely affected parasites,
these FVs appeared as multiple discontiguous vacuoles. In more
severely affected parasites, the vacuolar membrane was absent,
and hemozoin crystals were free within the cellular cytoplasm.
Inhibition of phosphatidylinositol 3-kinase function also
disrupts food vacuolar morphology. The morphological effects
of fosmidomycin-treated P. falciparum suggest a defect in hemoglobin trafficking in these cells. The phosphatidylinositol 3-kinase
(PI3-K) inhibitor wortmannin was previously demonstrated to
inhibit P. falciparum PI3-K in vitro and inhibit hemoglobin uptake
in malaria parasites (37). Since Rab GTPases often function
through the activation of PI3-Ks, we hypothesized that the ultrastructural abnormalities of fosmidomycin-treated parasites
would be similar to those of wortmannin-treated parasites. We
found that wortmannin caused a disruption in food vacuolar
morphology similar to that caused by fosmidomycin. In wortmannin-treated parasites, the FV appeared to be fragmented into
multiple discontiguous vacuoles (Fig. 6C). While a number of
abnormal traits characterized the FV of both fosmidomycin- and
wortmannin-treated cells, the most quantifiable change was the
loss of FV membrane or apparent fragmentation of a single FV
into multiple FVs. A series of representative electron micrographs
(⬎25 cells under each condition) were scored for FV morphology.
Abnormal FVs were defined by an absence of FV membrane or the
presence of more than one focus of hemozoin. Using these criteria, FV morphology was significantly altered upon fosmidomycin
and wortmannin treatments (P ⬍ 0.001 for each [t test]). While
the ultrastructural effects that we observed differed slightly from
what was previously reported for wortmannin-treated P. falcipa-

Eukaryotic Cell

Downloaded from http://ec.asm.org/ on December 12, 2013 by Washington University in St. Louis

FIG 3 Mislocalization of Rab5 proteins by fosmidomycin treatment. (A and B) Confocal immunofluorescence with either anti-PfRab5a (A) or anti-PfRab5c (B)

Isoprenoids in Malaria

stage parasites, 12 h after invasion) compared to those in which DNA replication has begun (S phase), as determined by acridine orange staining and flow
cytometric evaluation. Untreated parasites (A) are compared to fosmidomycin-treated parasites (B), fosmidomycin- and geranylgeraniol-treated parasites (C),
and parasites with geranylgeraniol treatment alone (D). The cell cycle duration under these conditions is approximately 48 h; untreated parasites return to pre-S
phase at 36 h.

rum, this may reflect the superior membrane preservation
achieved by the low-osmolality fixation technique used here (37).
Inhibition of isoprenoid biosynthesis or PI3-K function disrupts food vacuolar integrity. Both fosmidomycin and wortmannin treatment of P. falciparum resulted in abnormal FV morphologies, as visualized by electron microscopy. To independently
assess the integrity of the FV in fosmidomycin- and wortmannin-

treated parasites, we utilized a malaria parasite strain expressing
the hemoglobin-digesting enzyme plasmepsin II tagged with
green fluorescent protein (PMII-GFP). In malaria parasites,
PMII-GFP is localized to the FV (24). Using confocal immunofluorescence, we confirmed that PMII-GFP was localized to the FV,
which is distinguished microscopically in phase images by the
presence of dark hemozoin pigment (Fig. 7, left). Following fos-

FIG 6 Food vacuolar defect in fosmidomycin- and wortmannin-treated parasites. (A to C) Transmission electron microscopic evaluation of control parasites
(A) compared to parasites treated for 24 h with either the isoprenoid inhibitor fosmidomycin (B) or the PI3-K inhibitor wortmannin (C). On the right is a
magnified view of a hemozoin-containing FV. (D) Scoring of electron micrographs of control versus fosmidomycin (FSM)- and wortmannin-treated cells.
Abnormal FVs were defined as FVs that either lacked an FV membrane or contained more than one discontiguous membrane-bound collection of hemozoin
(n ⬎ 25 under each condition). ⴱ, P ⬍ 0.001 compared to untreated conditions (Fisher’s 2-tailed test).
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FIG 5 Fosmidomycin-treated parasites arrest during S phase. Shown are proportions of cells with unreplicated DNA (pre-S phase, morphologically early-ring-

Howe et al.

DISCUSSION

midomycin treatment, PMII-GFP was no longer discretely localized within the FV. Instead, PMII-GFP was dispersed throughout
the parasite cytoplasm, consistent with the physical disruption of
the FV that was visualized by electron microscopy (Fig. 7). PMIIGFP localization was restored by medium supplementation with
the isoprenoid geranylgeraniol, confirming that this effect of fosmidomycin is caused by an inhibition of isoprenoid biosynthesis.
PMII-GFP was diffusely present throughout the cytoplasm of
wortmannin-treated parasites, confirming that FVs are also disrupted upon PI3-K inhibition. Similar effects of fosmidomycin
and wortmannin on FV integrity were confirmed in live parasite
cells treated with Lysotracker Red (LR), a fluorophore that indicates acidic organelles. LR accumulated within the FV of control
parasites but was dispersed throughout the cytoplasm of fosmidomycin- and wortmannin-treated parasites (Fig. 7, right). FV localization was restored in fosmidomycin-treated parasites that were
rescued with medium supplementation with geranylgeraniol.

Isoprenoid biosynthesis via the nonmevalonate (MEP) pathway is
required for intraerythrocytic development of P. falciparum malaria parasites. Fosmidomycin-treated parasites arrest in the first
cell cycle following drug treatment, in contrast to the “delayed
death” that occurs in the second cell cycle of parasites treated with
other apicoplast-targeting antimalarial agents (such as clindamycin and doxycycline) (34). This is not unexpected, given that isoprenoids are expected to have multiple cellular functions outside
apicoplast maintenance. We find that fosmidomycin-treated parasites successfully generate digestive food vacuoles (FVs), initiate
hemoglobin digestion, and begin DNA replication prior to developmental arrest. De novo isoprenoid biosynthesis therefore does
not appear to be required for these complex and energy-intensive
cellular tasks, and this finding indicates a narrower role for isoprenoids in malaria cellular functions than had been suspected.
Our results suggest that the biological effects of isoprenoid
inhibition by fosmidomycin in P. falciparum are in part due to an

FIG 8 Apicoplast and parasitophorous vacuolar targeting in fosmidomycin- and wortmannin-treated parasites. Shown is live-cell fluorescence of malaria
parasites that express either the leader sequence (ACPL-GFP) (A) or signal sequence (ACPs-GFP) (B) from P. falciparum acyl carrier protein, fused to GFP, which
traffic to the apicoplast or parasitophorous vacuole, respectively (27). Untreated parasites (control) are compared to fosmidomycin (⫹FSM)- and wortmannin
(⫹wort)-treated parasites. Images are representative of at least three independent biological experiments.
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FIG 7 Loss of food vacuolar integrity upon fosmidomycin and wortmannin
treatment. Shown is the confocal fluorescence microscopic localization of a
plasmepsin II-GFP (P2-GFP) construct (left) or live fluorescence imaging of
Lysotracker Red-stained malaria parasites (right). Control parasites (A) are
compared to parasites treated for 24 h with either fosmidomycin (B), fosmidomycin plus geranylgeraniol (C), or wortmannin (D). Images are representative
of at least three independent biological experiments. Visualization of PMIIGFP in FSM- and wortmannin-treated parasites required higher detector gain
levels, resulting in increased observed erythrocyte autofluorescence.

To examine the possibility that the mislocalization of PMIIGFP was due to general defects in protein traffic or membrane
permeability, we evaluated the ability of drug-treated cells to appropriately localize two additional GFP fusion proteins with wellcharacterized localizations: the apicoplast localization sequence
from acyl carrier protein (ACP), ACPL-GFP (which traffics to the
apicoplast), and the signal sequence from ACP, ACPs-GFP (which
is exported to the parasitophorous vacuole space) (22). Both
ACPs- and ACPL-GFP were appropriately localized in both fosmidomycin- and wortmannin-treated cells (Fig. 8). ACPL-GFP
fluorescence in parasites with and without drug treatments demonstrated a typical apicoplast appearance, with a long, thin, single
structure early in intraerythrocytic development (38). With and
without drug treatment, ACPs-GFP fluorescence was present
within the parasitophorous vacuole and was frequently seen in the
tubovesicular network. These results indicate that general protein
trafficking mechanisms are still in place in both fosmidomycinand wortmannin-treated cells and support that the FV phenotype
and PMII-GFP localization observed in these cells are not an indirect effect of acute cellular injury.
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FIG 9 Model of fosmidomycin effects on malaria parasites. Fosmidomycin
blocks isoprenoid biosynthesis and causes a defect in growth and vesicular
trafficking to the food vacuole (FV). These effects are rescued by geranylgeraniol (GG-ol), indicating that the essential isoprenoids in malaria are
metabolically derived from geranylgeranyl pyrophosphate (GG-PP). GG-PP is
the substrate for geranylgeranyltransferase (GGTase), which modifies the endocytosis regulator Rab5 (a small GTPase) in most eukaryotes. Blocking of
isoprenoid biosynthesis (with fosmidomycin) decreases protein prenylation,
causes Rab5 mislocalization, and alters FV morphology. IPP, isopentenyl pyrophosphate; DMAPP, dimethylallyl pyrophosphate.

plain the ultrastructural defects observed for fosmidomycintreated parasites (graphically represented in Fig. 9). Expression of
a constitutively active Rab5a (Q102L) allele produces a bloated,
enlarged FV, the opposite effect of what we observed upon fosmidomycin treatment and Rab5 mislocalization (36). In addition
to the effects on food vacuolar morphology that we observed,
fosmidomycin was also previously reported to interrupt apicoplast development in P. falciparum (9). The lipid PI(3)P has been
localized to both the apicoplast and food vacuole, and PI3-K inhibition with wortmannin disrupts apicoplast development (35,
47) and alters food vacuolar morphology (this study). While
PI(3)P signaling and isoprenoid biology are both complex, these
phenotypic similarities suggest that the two pathways could converge and are consistent with the hypothesis that PI3-K may be a
Rab5 effector in P. falciparum.
Upon fosmidomycin treatment, both Rab5a and Rab5c are
found within the host erythrocyte. This mislocalization does not
appear to be due to general membrane permeability, since other
protein constructs are retained within the parasite plasma membrane or parasitophorous vacuole (PMII-GFP [Fig. 7] and ACPLGFP and ACPs-GFP [Fig. 8]). Since neither Rab5a nor Rab5c is
predicted to contain a host-targeting (HT) or Plasmodium export
element (PEXEL) motif, the localization of these proteins to the
host cell suggests an alternate mechanism of export that is unmasked when the proteins are not tethered by prenylation. Further experimentation is required to determine whether there is a
population of Rabs in P. falciparum that have biological functions
within the host erythrocyte under normal growth conditions.
As novel inhibitors are developed to target nonmevalonate isoprenoid biosynthesis, an understanding of the biological consequences of isoprenoid biosynthesis inhibition in P. falciparum
may inform the rational selection of secondary agents that will be
useful in combination therapy. For example, since fosmidomycintreated parasites arrest prior to completion of DNA synthesis,
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inhibition of protein prenylation. While the mitochondrial electron carrier ubiquinone is also likely essential, we find that malaria
parasites that have been engineered to bypass the need for electron
transport remain highly sensitive to fosmidomycin. Our results
implicate at least one further essential function of isoprenoid biosynthesis in malaria parasites and are consistent with findings reported previously by Yeh and DeRisi (unpublished data described
in reference11). We present the first evidence that the isoprenyl
metabolites used in protein prenylation are derived from de novo
isoprenoid biosynthesis, since protein prenylation is reduced by
isoprenoid biosynthesis inhibition. Protein prenylation is necessary for proper protein localization and function of prenylated
proteins, and indeed, we find that inhibition of isoprenoid biosynthesis causes a dramatic mislocalization of two candidate prenyltransferase substrates (Rab5a and Rab5c). Finally, inhibition of
isoprenoid biosynthesis causes food vacuolar morphological defects that are consistent with a disruption of protein prenylation.
Inhibition of protein prenylation directly with prenyltransferase
inhibitors causes a more rapid cell cycle arrest than we observed
(16); however, this is consistent with our previously reported findings that the levels of isoprenoid precursors do not change for 6 h
following fosmidomycin treatment (12).
The intraerythrocytic stage of P. falciparum depends on digestion of host cell hemoglobin as its source for most amino acids
(27). Hemoglobin is transported from the host cell to a specialized
acidic digestive structure, the FV, where proteolysis and heme
detoxification occur. Hemoglobin trafficking to the FV is a complicated, actin-dependent process, the molecular details of which
have not been fully elucidated (36, 39, 40). The Rab family of small
GTPases is likely to be important for this process. There are at least
11 Rab family homologs in the P. falciparum genome (41). Of
these, Rab5 homologs in particular are important for early endocytosis in other eukaryotes, including other protozoans, such as
the related apicomplexan Toxoplasma gondii as well as Leishmania
donovani and Entamoeba histolytica (42–44). In P. falciparum,
Rab5a, a prototypical early endosomal marker, has been localized
to small hemoglobin-containing vesicles by immunoelectron microscopy, suggesting that these are endocytic vesicles en route to
the FV (36).
Activated GTP-bound Rab5s typically function through activation of phosphatidylinositol-3 kinases (PI3-Ks) to increase local
levels of phosphatidylinositol 3-phosphate [PI(3)P]. Although casein kinase physically associates with Rab5b, the downstream effectors of Rab5s in malaria are not known (30). A single essential,
wortmannin-sensitive PI3-K has been described for P. falciparum,
which can synthesize PI(3)P, PI(3,4)P2, and PI(3,4,5)P3 (35, 37).
PI(3)P is the dominant phosphorylated phosphatidylinositol in
malaria-infected erythrocytes and appears to have a large number
of functional roles in malaria parasites (35). Using specific PI(3)Pbinding proteins, PI(3)P has been localized to the food vacuole,
the apicoplast, and the endoplasmic reticulum in malaria parasites
(35, 45, 46). Surprisingly, PI(3)P binding by export signals appears to be required for malaria protein export to the host cell, and
PI3-K itself is exported to the host erythrocyte (37, 45).
The growth arrest and morphological changes of fosmidomycin-treated malaria parasites may reflect multiple cellular insults.
Decreased protein prenylation upon fosmidomycin treatment is
likely to result in mislocalization of multiple prenyltransferase
substrates, including all Rab family members. For example, a loss
of Rab5 prenylation and defective trafficking to the FV could ex-
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small molecules that act on parasite egress, such as PfSUB1 protease inhibitors (48), may be less useful alongside inhibition of
isoprenoid biosynthesis. Our results suggest that parasite-specific
prenyltransferase inhibitors may be particularly useful in combination antimalarial therapy with isoprenoid biosynthesis inhibitors.
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